LARGO, Fla.,
In the most recent research report issued by
Additionally, GeoPharma has a speaking engagement at the Red Chip Small
Cap Investor Conference in
For those unable to attend in person, the presentation may be viewed online by logging in to the following site: http://www.visualwebcaster.com/event.asp?id=45650.
Speaking about GeoPharma, Red Chip
GeoPharma will also be an attending presenter at the Spring EdgeWater
Research Partners conference being held at the Grand Hyatt in
Commenting on GeoPharma, EdgeWater Research analyst and publisher
Furthermore, GeoPharma has announced that it plans to release its 3rd
quarter earnings report prior to trading on
A replay of the call will also be available from
About GeoPharma, Inc:
GeoPharma, Inc. is a rapidly growing Bio/Pharma company with a diversified business model participating in 3 main market segments: Specialty Pharma, Manufacturing, and Distribution. The Specialty Pharma division specializes in the formulation of generic drugs for human and veterinary usage and the development of medical devices used by oncologists and other medical professionals. The Manufacturing and Distribution divisions, manufacture, package, and distribute generic drugs, nutraceuticals, cosmetics, and functional food products for companies worldwide.
GeoPharma's growth strategy is to capitalize on its research and manufacturing expertise to develop medical devices and high margin generic drug products for niche markets with high barriers to entry. GeoPharma's competitive advantage in these areas is in its ability to navigate the challenges that such market pursuits present effectively.
Currently GeoPharma employs nearly 300 people and operates facilities in Florida, Maryland, Pennsylvania, Nevada, Rhode Island, and Texas utilizing over 330,000 Sq. Ft. of office, warehouse, manufacturing and laboratory facilities.
For further information visit the 'For Investors' section of the GeoPharma website at www.geopharmainc.com.
This press release may contain statements, which constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.
SOURCE GeoPharma, Inc.
